Brief Communication | Published:

Molecular targets for therapy

Constitutive activation of nuclear factor kappa B-inducing kinase counteracts apoptosis in cells with rearranged mixed lineage leukemia gene

Leukemiavolume 32pages24982501 (2018) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Winters AC, Bernt KM. MLL-rearranged leukemias—an update on science and clinical approaches. Front Pediatr. 2017;5:4.

  2. 2.

    Cornelissen JJ, Versluis J, Passweg JR, van Putten WL, Manz MG, Maertens J, et al. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia. 2015;29:1041–50.

  3. 3.

    Kuo HP, Wang Z, Lee DF, Iwasaki M, Duque-Afonso J, Wong SH, et al. Epigenetic roles of MLL oncoproteins are dependent on NF-kappaB. Cancer Cell. 2013;24:423–37.

  4. 4.

    Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12:115–30.

  5. 5.

    Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood. 2010;115:3541–52.

  6. 6.

    Saitoh Y, Yamamoto N, Dewan MZ, Sugimoto H, Martinez Bruyn VJ, Iwasaki Y, et al. Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. Blood. 2008;111:5118–29.

  7. 7.

    Sun S-C. The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17:545.

  8. 8.

    Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa JC, Wilhelm JS, et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 2008;13:483–95.

  9. 9.

    Becker MW, Jordan CT. Leukemia stem cells in 2010: current understanding and future directions. Blood Rev. 2011;25:75–81.

  10. 10.

    Mulloy JC, Jankovic V, Wunderlich M, Delwel R, Cammenga J, Krejci O, et al. AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. Proc Natl Acad Sci USA. 2005;102:4016–21.

  11. 11.

    Fernandes MT, Ghezzo MN, Silveira AB, Kalathur RK, Póvoa V, Ribeiro AR, et al. Lymphotoxin-β receptor in microenvironmental cells promotes the development of T-cell acute lymphoblastic leukaemia with cortical/mature immunophenotype. Br J Haematol. 2015;171:736–51.

  12. 12.

    Migliazza A, Lombardi L, Rocchi M, Trecca D, Chang CC, Antonacci R, et al. Heterogeneous chromosomal aberrations generate 3’ truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. Blood. 1994;84:3850–60.

  13. 13.

    Jin HR, Jin X, Lee JJ. Zinc-finger protein 91 plays a key role in LIGHT-induced activation of non-canonical NF-kappaB pathway. Biochem Biophys Res Commun. 2010;400:581–6.

  14. 14.

    Jin X, Jin HR, Jung HS, Lee SJ, Lee JH, Lee JJ. An atypical E3 ligase zinc finger protein 91 stabilizes and activates NF-kappaB-inducing kinase via Lys63-linked ubiquitination. J Biol Chem. 2010;285:30539–47.

  15. 15.

    Unoki M, Okutsu J, Nakamura Y. Identification of a novel human gene, ZFP91, involved in acute myelogenous leukemia. Int J Oncol. 2003;22:1217–23.

  16. 16.

    Levkau B, Scatena M, Giachelli CM, Ross R, Raines EW. Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF-κB loop. Nat Cell Biol. 1999;1:227–33.

Download references


The authors kindly thank Prof. J.C. Mulloy and Dr. M. Wunderlich for providing CD34+MLL-AF9 and CD34+AML1-ETO cells, respectively. This work was supported by grants from the German Federal Ministry of Education and Research (e:Bio, 031A304) and the Ministry of Economy, Research and Digitalization of Saxony-Anhalt (support from the European Fund for Regional Development (EFRD) (ZS/2016/04/78155)) to MN.

Author contributions:

MS-T and MN designed the study. MS-T and GM performed experiments. MS-T, MHF, and MN analyzed and interpreted the data. MS-T, MHF, GM, and MN wrote and revised the manuscript.

Author information


  1. Institute of Experimental Internal Medicine, Medical Faculty, Otto von Guericke University, Magdeburg, Germany

    • Maja Studencka-Turski
    • , Gunter Maubach
    • , Michael Hartmut Feige
    •  & Michael Naumann


  1. Search for Maja Studencka-Turski in:

  2. Search for Gunter Maubach in:

  3. Search for Michael Hartmut Feige in:

  4. Search for Michael Naumann in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Michael Naumann.

Electronic supplementary material

About this article

Publication history